Arena Pharmaceuticals Inc

Arena Pharmaceuticals — JP Morgan Healthcare Conference 2017

28 slides from Arena Pharmaceuticals's conference presentation, Jan 6, 2017

  1. Slide 1: Corporate Presentation – JP Morgan Healthcare Conference

    Slide 1: Corporate Presentation – JP Morgan Healthcare Conference

    Non-Confidential January 2017 Corporate Presentation JP Morgan Healthcare Conference Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our focus, goals, strategy, plans, timelines and guidance; research and development (R&D) programs and BELVIQ, including with respect to poten

  3. Slide 3: Arena Evolved Executive Summary

    Slide 3: Arena Evolved Executive Summary

    Arena Evolved Executive Summary From research-based to a streamlined, focused high-performing clinical development organization Three unencumbered Phase 2 potentially first- or best-in-class programs Significant readouts in 2017: Etrasimod Ralinepag APD371 Nelotanserin Revitalized team Dynamic appro

  4. Slide 4: Research Platform and Belviq Restructuring Reducing Costs on Non-Core Assets

    Slide 4: Research Platform and Belviq Restructuring Reducing Costs on Non-Core Assets

    Research Platform and Belviq Restructuring Reducing Costs on Non-Core Assets Discovery research was driving ~$25M in annual expenditure for Arena Spin out into independent organization – Beacon Discovery - by Dr. Dominic Behan, co-founder of Arena Arena retains certain rights and economics on assets

  5. Slide 5: Focus on Pipeline: Differentiated Assets with High-Value Potential

    Slide 5: Focus on Pipeline: Differentiated Assets with High-Value Potential

    Program Therapeutic Area/Indication Pre- Clinical Phase 1 Phase 2 Phase 3 Post Market Data Timing Internal Programs Etrasimod Optimized Activity S1P Receptor Modulator Lead Indication: Ulcerative Colitis (UC) Exploratory Indications: Extra-Intestinal Manifestations (EIM) Pyoderma Gangrenosum (PG) Pr

  6. Slide 6: Clinical Development Focus and Revamped Operational Team

    Slide 6: Clinical Development Focus and Revamped Operational Team

    Clinical Development Focus and Externally-Driven Thinking Supported by Revamped Operational Team Amit Munshi, President and CEO CEO, Epirus and Percivia (sold to JNJ) Founder, CBO, Kythera (sold to Allergan) Kevin Lind, Chief Financial Officer TSSP / TPG Pharma Partners Lehman Brothers Cheryl Lassen

  7. Slide 7: Etrasimod

    Slide 7: Etrasimod

    Oral, Next Generation, S1P Receptor Modulator Optimized Activity Being Evaluated for Multiple Autoimmune Diseases Etrasimod

  8. Slide 8: Etrasimod (APD334) - Potentially Best-in-Class Profile

    Slide 8: Etrasimod (APD334) - Potentially Best-in-Class Profile

    Etrasimod (APD334) - Potentially Best-in-Class Profile Based on Preclinical and Clinical Data Status High specificity for appropriate receptor sub types Decreased lymphocyte counts with rapid recovery Potentially improved safety profile Data to Date Phase 2 multinational trial in ulcerative colitis

  9. Slide 9: Significant Market Potential in Inflammatory Bowel Disease, Specifically Ulcerative Colitis

    Slide 9: Significant Market Potential in Inflammatory Bowel Disease, Specifically Ulcerative Colitis

    Aminosalicylates (5-ASAs) Corticosteroids (Acute Therapy) Immunosuppressants TNF-α Blockers Integrin Receptor Antagonists S1P Receptor Modulators Significant Market Potential in Inflammatory Bowel Disease (IBD), Specifically Ulcerative Colitis UC market of ~2M patients and $3.7B in global drug sales

  10. Slide 10: Etrasimod Clinical Program Expanding Indications

    Slide 10: Etrasimod Clinical Program Expanding Indications

    Etrasimod Clinical Program Expanding Indications 1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122 2. Decision Resources 3. Br J Dermatol. 2015 Jul;173(1):275-8.

  11. Slide 11: Etrasimod's Optimized Activity Profile Characteristics May Avoid Off Target Activity

    Slide 11: Etrasimod's Optimized Activity Profile Characteristics May Avoid Off Target Activity

    Designed to selectively modulate S1P receptors believed to be associated with autoimmune modulation while avoiding those associated with deleterious side-effects Etrasimod’s Optimized Activity Profile Characteristics May Avoid Off Target Activity *Data on file Associated with cardiac, pulmonary & po

  12. Slide 12: Early Studies Suggest Robust Lymphocyte Reduction and Strong Safety Profile

    Slide 12: Early Studies Suggest Robust Lymphocyte Reduction and Strong Safety Profile

    In Early Studies Etrasimod Data Suggests Robust Lymphocyte Reduction and Strong Safety Profile Observed Lymphocyte Counts (Mean) Non-Titrated First Dose HR Mean lymphocyte counts decrease up to 69% Half-life ~35 Hours Lymphocyte lowering ~60 - 70% correlates with efficacy in psoriasis, UC & other au

  13. Slide 13: Emerging as a Potential Best-in-Class S1P Modulator

    Slide 13: Emerging as a Potential Best-in-Class S1P Modulator

    No symptomatic bradycardia No heart block (therapeutic dose) Based on Early Clinical Data Etrasimod Emerging as a Potential Best-in-Class S1P Modulator Excellent Lymphocyte Modulation 60-70% reduction in lymphocyte counts Recovery to baseline within one week Encouraging CV Safety Profile Clean Hepat

  14. Slide 14: Ralinepag

    Slide 14: Ralinepag

    An Oral, Selective IP Receptor Agonist Targeting the Prostacyclin Pathway for the Treatment of Pulmonary Arterial Hypertension (PAH) Ralinepag

  15. Slide 15: Ralinepag (APD811) - Potentially Best-in-Class Profile

    Slide 15: Ralinepag (APD811) - Potentially Best-in-Class Profile

    Ralinepag (APD811) - Potentially Best-in-Class Profile - Unique Receptor Activation & Pharmacokinetics Status Ralinepag demonstrated superior in-vitro performance, compared to selexipag in: Functional G-protein activation (cAMP) Potency for inhibition of vascular remodeling & vasodilation Potency fo

  16. Slide 16: Significant Market Potential for Oral Prostacyclin Agonists with Improved PK

    Slide 16: Significant Market Potential for Oral Prostacyclin Agonists with Improved PK

    Oral Monotherapy Oral Combos Inhaled/SC/IV Significant Market Potential for Oral Prostacyclin Agonists with Improved PK A novel, potent oral prostacyclin agonist with improved PK could address a greater portion of the $4B PAH global market IP agonists are the only class of PAH drugs shown to reduce

  17. Slide 17: Ralinepag Data Suggests Improved Potency and Efficacy vs. Selexipag

    Slide 17: Ralinepag Data Suggests Improved Potency and Efficacy vs. Selexipag

    Ralinepag Data Suggests Improved Potency and Efficacy vs. Selexipag (MRE-269) Metric Iloprost (IV) Ralinepag (oral) MRE-269 (oral) Functional G-protein activation (cAMP) Potency 3.3 nM 24 nM 151 nM Efficacy 100 % 67 % 48 % Potency for inhibition of vascular remodeling & vasodilation IC50 56 nM 14 nM

  18. Slide 18: Ralinepag Pharmacokinetic Profile

    Slide 18: Ralinepag Pharmacokinetic Profile

    Ralinepag Pharmacokinetic Profile Optimal Exposure in Therapeutic Range Ralinepag IR Has Better Exposure for Inhibition of Vascular Remodeling Compared to Selexipag In Vitro MRE-269 after Selexipag, 1.6 mg bid, Fasted Ralinepag, 0.2 mg bid, Fasted Ralinepag XR PK at steady state has optimized “IV-li

  19. Slide 19: Ralinepag is a Potential Best-in-Class Oral IP Agonist

    Slide 19: Ralinepag is a Potential Best-in-Class Oral IP Agonist

    Ralinepag is a Potential Best-in-Class Oral Prostacyclin Receptor (IP) Agonist Potency High intrinsic potency & activity at human IP receptor compared to other oral compounds Superior target tissue responses in patient-derived samples Inhibition of platelet aggregation, smooth muscle cell proliferat

  20. Slide 20: APD371

    Slide 20: APD371

    APD371 Peripherally Restricted, Highly–Selective, Full Agonist to Cannabinoid 2 Receptor (CB2) Being Evaluated for Treatment of Pain Associated with Crohn’s Disease

  21. Slide 21: APD371 - Potentially First-in-Class Profile

    Slide 21: APD371 - Potentially First-in-Class Profile

    APD371 - Potentially First-in-Class Profile Emerging Based on Preclinical and Clinical Data Phase 2 start early 2017 Data expected by year-end 2017 Superior pain option to opioids and other CB2 programs Highly selective, peripherally restricted avoids psychotropic activity Full CB2 receptor agonism

  22. Slide 22: APD371 Program Review: Types of Pain

    Slide 22: APD371 Program Review: Types of Pain

    APD371 Program Review Types of Pain Visceral pain represents the most attractive and appropriate opportunity Figure adapted from Melnikova, Nature Reviews Drug Discovery, 2010 1. US general population, Kappelman et al. (2007) Clin Gastroenterol Hepatol 5:1424 2. US general population, Berry et al. (

  23. Slide 23: Many Crohn's Disease Patients Continue to Experience Pain Even in Remission

    Slide 23: Many Crohn's Disease Patients Continue to Experience Pain Even in Remission

    Many Crohn’s Disease Patients Continue to Experience Pain Even in Remission *Source: National Center for Biotechnology Information Available pain medications are associated with significant issues limiting use in Crohn’s disease Market Overview ~2.3M IBD patients diagnosed in major markets in 2015 ~

  24. Slide 24: CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells

    Slide 24: CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells

    CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells Within GI Tract Both humans & rodents have CB2 receptors located in target tissue GI & local immune cells: Epithelial cells Immune cells Enteric neurons CB2 receptor also expressed on visceral afferent nerves During inflammat

  25. Slide 25: Strong Preclinical Support for APD371 in Intestinal Pain

    Slide 25: Strong Preclinical Support for APD371 in Intestinal Pain

    Strong preclinical support for APD371 as a potent, selective full agonist to CB2 in intestinal pain Preclinical Studies Suggest CB2 Activation is Important for Regulation of Intestinal Pain In Crohn’s, the Endocannabinoid System, including CB2, is Dysregulated Several Animal Studies Provide Evidence

  26. Slide 26: APD371 is a Highly Selective, Full Agonist to CB2 for Crohn's Pain

    Slide 26: APD371 is a Highly Selective, Full Agonist to CB2 for Crohn's Pain

    APD371 is a Highly Selective, Full Agonist to CB2 for Crohn’s Pain – a Major Unmet Need Selective, Full Agonist Full agonists show efficient receptor internalization and efficacy in vivo Previous CB2 programs have been partial agonists CB2 expressed across multiple cell types in GI tract In GI pain,

  27. Slide 27: Arena Evolved Executive Summary

    Slide 27: Arena Evolved Executive Summary

    Arena Evolved Executive Summary From research-based to a streamlined, focused high-performing clinical development organization Three unencumbered Phase 2 potentially first- or best-in-class programs Significant readouts in 2017: Etrasimod Ralinepag APD371 Nelotanserin Revitalized team Dynamic appro

  28. Slide 28: Thank you

    Slide 28: Thank you

    PHARMACEUTICALS Thank you NASDAQ: ARNA

Source: SEC EDGAR · 8-K filed Jan 6, 2017

More decks from Arena Pharmaceuticals Inc